SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

<p>SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE long-term extension study Safety profile of SYFOVRE in GALE was consistent with previously reported clinical data Data presented during an oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting A Media […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/syfovre-pegcetacoplan-injection-continued-to-demonstrate-increasing-treatment-effects-over-30-months-in-patients-with-geographic-atrophy-ga/">SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>